https://www.selleckchem.com/products/gdc-0068.html
To assess vision, injection quantity, initial lesion size, and final anatomic status in patients with nAMD completing the treat-extend-stop (TES) protocol. Patients with nAMD received ≥ 3 monthly anti-VEGF injections followed by 1-2week injection interval extensions, with intra/subretinal fluid resolution on SD-OCT, to 12weeks. With quiescent disease, and 2 quarterly injections, patients were monitored alone beginning at 4weeks extending by 1-2week intervals until quarterly monitoring. Eighty-eight of 143 eyes with nAMD completed the T
Like
Comment
Share
